Imatinib Mesylate Tablet, Film Coated
Product Images NDC 59651-241

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 59651-241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Imatinib Fig1)

A Kaplan-Meier curve chart titled 'Progression Free Survival (ITT Principle)' comparing Imatinib Mesylate and IFN+Ara-C treatment arms over 72 months since randomization. The y-axis shows the percentage of patients without progression, and the x-axis shows months. The chart includes data on number of patients with progression, censored at discontinuation and last follow-up, hazard ratio, confidence interval, and p-value for the log-rank test.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Imatinib Fig2)

A line graph titled 'Time to Progression to AP or BC (ITT Principle)' comparing Imatinib Mesylate and IFN+Ara-C arms over 72 months since randomization. The Y-axis represents the percentage without progression to AP/BC, ranging from 0 to 100%. The chart includes patient numbers for progression, censoring, and hazard ratio with confidence intervals and statistical significance.*

FDA Label Image

Package Label-principal Display Panel (100 mg)

A Kaplan-Meier survival curve titled 'Study 1 Recurrence-Free Survival (ITT Population)' showing probability of being alive and recurrence-free over survival time in months. The graph compares Imatinib 400 mg with placebo, indicating higher recurrence-free survival probability for Imatinib. Patient counts at risk are listed below the time axis for both groups.*

FDA Label Image

Package Label-principal Display Panel (400 mg)

A Kaplan-Meier curve presenting recurrence-free survival over time in months for two Imatinib treatment groups from Study 2 (ITT population). The graph shows probability of recurrence-free survival on the y-axis and survival time in months on the x-axis, comparing Imatinib at 12 months versus 36 months, including censored observations and statistical data like hazard ratio and p-value.*

FDA Label Image

Package Label-principal Display Panel (400 mg (Blister Carton Label))

A Kaplan-Meier survival curve titled 'Study 2 Overall Survival (ITT Population)' showing the probability of overall survival over time in months for two groups treated with Imatinib Mesylate at 12 months and 36 months. The y-axis represents the probability of overall survival, and the x-axis shows survival time in months up to 84 months. The chart includes hazard ratio, P-value, and numbers at risk with events reported below the graph, emphasizing survival analysis data for Imatinib Mesylate treatment durations.*

FDA Label Image

Imatinib Fig6

Label for Imatinib Mesylate Tablets 100 mg by Aurobindo Pharma Limited. The film-coated tablets come in a package of 90 tablets. The label includes storage instructions, manufacturer and distributor information, and a barcode. The strength is prominently displayed in a purple oval near the product name.*

FDA Label Image

Imatinib Fig7

Label for Imatinib Mesylate Tablets 400 mg film-coated tablets by Aurobindo Pharma Limited. The label displays dosage strength, quantity of 30 tablets, storage instructions, distributor details (Aurobindo Pharma USA, Inc.), and a barcode. The tablets are for oral use and packaged in a tight container as per USP standards.*

FDA Label Image

Imatinib Fig8

Imatinib Mesylate Tablets 400 mg film-coated oral tablets packaging label from Aurobindo Pharma. The label indicates 30 unit-dose tablets (3 x 10) with the NDC 59651-241-03. The package features dosage strength prominently with the Aurobindo logo and a small image of an oblong brown tablet.*

FDA Label Image

Chemical Structure (Imatinib Str)

Chemical structure of Imatinib Mesylate, showing its molecular arrangement including multiple aromatic rings, nitrogen atoms, and a mesylate group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.